Literature DB >> 30859582

Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography.

Cyrielle Caussy1,2, Meera Bhargava1, Ida F Villesen3, Natasja S Gudmann3, Diana J Leeming3, Morten A Karsdal3, Claire Faulkner1, Denny Bao1, Amy Liu1, Min-Tzu Lo4, Ricki Bettencourt1,5, Shirin Bassirian1, Lisa Richards1, David A Brenner1,6, Chi-Hua Chen4, Claude B Sirlin7, Rohit Loomba1,5,6.   

Abstract

N-terminal propeptide of type 3 procollagen (PRO-C3) is a biomarker of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). This study examines the association between PRO-C3 concentration and liver fibrosis assessed by magnetic resonance elastography (MRE)-measured stiffness (MRE-stiffness) and the heritability of PRO-C3 concentration in a cohort of twins and families with and without NAFLD. We performed a cross-sectional analysis of a well-characterized prospective cohort of 306 participants, including 44 probands with NAFLD-cirrhosis and their 72 first-degree relatives, 24 probands with NAFLD without advanced fibrosis and their 24 first-degree relatives, and 72 controls without NAFLD and their 72 first-degree relatives. Liver steatosis was assessed by magnetic resonance imaging proton density fat fraction, and liver fibrosis was assessed by MRE-stiffness. Serum PRO-C3 was assessed by competitive, enzyme-linked immunosorbent assay. We assessed the familial correlation of PRO-C3 concentration, the shared gene effects between PRO-C3 concentration and liver steatosis and fibrosis, and the association between PRO-C3 concentration and genetic variants in the patatin-like phospholipase domain-containing 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), membrane-bound O-acyltransferase domain-containing (MBOAT), and glucokinase regulator (CGKR) genes. In multivariable-adjusted models including age, sex, body mass index, and ethnicity, serum PRO-C3 correlated strongly with liver fibrosis (r2  = 0.50, P < 0.001) and demonstrated robust heritability (h2 , 0.36; 95% confidence interval [CI], 0.07, 0.59; P = 0.016). PRO-C3 concentration and steatosis had a strong genetic correlation (shared genetic determination: 0.62; 95% CI, 0.236, 1.001; P = 0.002), whereas PRO-C3 concentration and fibrosis had a strong environmental correlation (shared environmental determination: 0.55; 95% CI, 0.317, 0.717; P < 0.001). PRO-C3 concentrations were higher in carriers of the TM6SF2 rs58542926-T allele compared with noncarriers: 15.7 (± 10.5) versus 10.8 (± 5.7) ng/L (P = 0.047).
Conclusion: Serum PRO-C3 correlates with MRE-assessed fibrosis, is heritable, shares genetic correlation with liver steatosis and shares environmental correlation with liver fibrosis. PRO-C3 concentration appears to be linked to both fibrosis and steatosis and increased in carriers of the TM6SF2 rs58542926 risk allele.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30859582      PMCID: PMC6984974          DOI: 10.1002/hep.30610

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  49 in total

1.  Power of the classical twin design revisited.

Authors:  Peter M Visscher
Journal:  Twin Res       Date:  2004-10

Review 2.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

3.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

4.  The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.

Authors:  Rosellina Margherita Mancina; Paola Dongiovanni; Salvatore Petta; Piero Pingitore; Marica Meroni; Raffaela Rametta; Jan Borén; Tiziana Montalcini; Arturo Pujia; Olov Wiklund; George Hindy; Rocco Spagnuolo; Benedetta Maria Motta; Rosaria Maria Pipitone; Antonio Craxì; Silvia Fargion; Valerio Nobili; Pirjo Käkelä; Vesa Kärjä; Ville Männistö; Jussi Pihlajamäki; Dermot F Reilly; Jose Castro-Perez; Julia Kozlitina; Luca Valenti; Stefano Romeo
Journal:  Gastroenterology       Date:  2016-02-02       Impact factor: 22.682

5.  Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Veeral Ajmera; Charlie C Park; Cyrielle Caussy; Seema Singh; Carolyn Hernandez; Ricki Bettencourt; Jonathan Hooker; Ethan Sy; Cynthia Behling; Ronghui Xu; Michael S Middleton; Mark A Valasek; Claire Faulkner; Emily Rizo; Lisa Richards; Claude B Sirlin; Rohit Loomba
Journal:  Gastroenterology       Date:  2018-04-13       Impact factor: 22.682

6.  Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.

Authors:  N S Patel; M R Peterson; D A Brenner; E Heba; C Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2013-02-05       Impact factor: 8.171

7.  The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters.

Authors:  Mette J Nielsen; Anders F Nedergaard; Shu Sun; Sanne S Veidal; Lise Larsen; Qinlong Zheng; Charlotte Suetta; Kim Henriksen; Claus Christiansen; Morten A Karsdal; Diana J Leeming
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

8.  Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.

Authors:  Mette J Nielsen; Sanne S Veidal; Morten A Karsdal; Diana J Ørsnes-Leeming; Ben Vainer; Stephen D Gardner; Robert Hamatake; Zachary D Goodman; Detlef Schuppan; Keyur Patel
Journal:  Liver Int       Date:  2014-10-29       Impact factor: 5.828

9.  Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.

Authors:  P Dongiovanni; S Stender; A Pietrelli; R M Mancina; A Cespiati; S Petta; S Pelusi; P Pingitore; S Badiali; M Maggioni; V Mannisto; S Grimaudo; R M Pipitone; J Pihlajamaki; A Craxi; M Taube; L M S Carlsson; S Fargion; S Romeo; J Kozlitina; L Valenti
Journal:  J Intern Med       Date:  2017-12-27       Impact factor: 8.989

10.  Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study.

Authors:  Rohit Loomba; Tanya Wolfson; Brandon Ang; Jonathan Hooker; Cynthia Behling; Michael Peterson; Mark Valasek; Grace Lin; David Brenner; Anthony Gamst; Richard Ehman; Claude Sirlin
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

View more
  4 in total

1.  A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.

Authors:  Tae Gyu Oh; Susy M Kim; Cyrielle Caussy; Ting Fu; Jian Guo; Shirin Bassirian; Seema Singh; Egbert V Madamba; Ricki Bettencourt; Lisa Richards; Ruth T Yu; Annette R Atkins; Tao Huan; David A Brenner; Claude B Sirlin; Michael Downes; Ronald M Evans; Rohit Loomba
Journal:  Cell Metab       Date:  2020-06-30       Impact factor: 27.287

2.  Cysteine-rich domain of type III collagen N-propeptide inhibits fibroblast activation by attenuating TGFβ signaling.

Authors:  Becky K Brisson; Daniel C Stewart; Chelsea Burgwin; David Chenoweth; Rebecca G Wells; Sherrill L Adams; Susan W Volk
Journal:  Matrix Biol       Date:  2022-03-24       Impact factor: 10.447

3.  Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.

Authors:  Marie Boyle; Dina Tiniakos; Jorn M Schattenberg; Vlad Ratziu; Elisabetta Bugianessi; Salvatore Petta; Claudia P Oliveira; Olivier Govaere; Ramy Younes; Stuart McPherson; Pierre Bedossa; Mette J Nielsen; Morten Karsdal; Diana Leeming; Stuart Kendrick; Quentin M Anstee
Journal:  JHEP Rep       Date:  2019-07-04

4.  Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease.

Authors:  Angelo Armandi; Chiara Rosso; Aurora Nicolosi; Gian Paolo Caviglia; Maria Lorena Abate; Antonella Olivero; Daphne D'Amato; Marta Vernero; Melania Gaggini; Giorgio Maria Saracco; Davide Giuseppe Ribaldone; Diana Julie Leeming; Amalia Gastaldelli; Elisabetta Bugianesi
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.